Repligen Corporation (RGEN), a life sciences company, Thursday reported net loss of $33.87 million or $0.60 per share for the fourth quarter, wider than $16.45 million or $0.29 per share loss in the same quarter a year ago.
Excluding one-time items, the company posted earnings of $25.13 million or $0.44 per share, that beat the analysts' average estimate of $0.41 per share. Analysts' estimates typically exclude special items.
Revenue for the quarter slightly increased to $167.55 million from $166.62 million in the previous year. The consensus estimate was for $167.57 million.
For the full year, the company expects revenue in the range of $685 million - $710 million. It sees EPS of $0.90 - $0.99, and adjusted EPS of $1.67 - $1.76. Analysts expect the company to report earnings of $1.71 per share on revenue of $692.76 million for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.